<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               2 DOSAGE AND ADMINISTRATION<BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           Administer at 6 mg/kg every 14 days as an intravenous infusion over 60 minutes (≤ 1000 mg) or 90 minutes (> 1000 mg). (2)<BR>                           Infusion reactions: Reduce infusion rate by 50% for mild reactions; terminate the infusion for severe infusion reactions. Depending on the severity and/or persistence of the reaction, permanently discontinue Vectibix. (2.1)<BR>                           Dermatologic toxicities: Withhold for severe or intolerable toxicity; may resume at 50% of dose if toxicity improves. (2.1)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.1 Recommended Dose and Dose Modifications<BR>                     <BR>                        The recommended dose of Vectibix is 6 mg/kg, administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes [see Dosage and Administration (2.2)]. <BR>                        Appropriate medical resources for the treatment of severe infusion reactions should be available during Vectibix infusions.<BR>                        <BR>                           Dose Modifications for Infusion Reactions<BR>                            [see Boxed Warning, Warnings and Precautions (5.2), and Adverse Reactions (<BR>                                 6.1<BR>                              , 6.3)]<BR>                        <BR>                        <BR>                           Reduce infusion rate by 50% in patients experiencing a mild or moderate (grade 1 or 2) infusion reaction for the duration of that infusion. <BR><BR>                           Terminate the infusion in patients experiencing severe infusion reactions. Depending on the severity and/or persistence of the reaction, permanently discontinue Vectibix.<BR>                        <BR>                        <BR>                           <BR>                              Dose Modifications for Dermatologic Toxicity<BR>                            [see Boxed Warning, Warnings and Precautions (5.1), and Adverse Reactions (<BR>                                 6.1<BR>                              )] <BR>                        <BR>                        <BR>                           Withhold Vectibix for dermatologic toxicities that are grade 3 or higher or are considered intolerable. If toxicity does not improve to ≤ grade 2 within 1 month, permanently discontinue Vectibix. <BR><BR>                           If dermatologic toxicity improves to ≤ grade 2, and the patient is symptomatically improved after withholding no more than two doses of Vectibix, treatment may be resumed at 50% of the original dose. <BR><BR>                                 If toxicities recur, permanently discontinue Vectibix. <BR><BR>                                 If toxicities do not recur, subsequent doses of Vectibix may be increased by increments of 25% of the original dose until the recommended dose of 6 mg/kg is reached. <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.2 Preparation and Administration<BR>                     <BR>                        Do not administer Vectibix as an intravenous push or bolus.<BR>                        <BR>                           Preparation <BR>                        <BR>                        Prepare the solution for infusion, using aseptic technique, as follows: <BR>                        <BR>                           Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Although Vectibix should be colorless, the solution may contain a small amount of visible translucent-to-white, amorphous, proteinaceous, panitumumab particulates (which will be removed by filtration; see below). Do not shake. Do not administer Vectibix if discoloration is observed.<BR><BR>                           Withdraw the necessary amount of Vectibix for a dose of 6 mg/kg. <BR><BR>                           Dilute to a total volume of 100 mL with 0.9% sodium chloride injection, USP. Doses higher than 1000 mg should be diluted to 150 mL with 0.9% sodium chloride injection, USP. Do not exceed a final concentration of 10 mg/mL. <BR><BR>                           Mix diluted solution by gentle inversion. Do not shake. <BR>                        <BR>                        <BR>                           Administration<BR>                        <BR>                        <BR>                           Administer using a low-protein-binding 0.2 μm or 0.22 μm in-line filter. <BR><BR>                           Vectibix must be administered via infusion pump. <BR><BR>                                 Flush line before and after Vectibix administration with 0.9% sodium chloride injection, USP, to avoid mixing with other drug products or intravenous solutions. Do not mix Vectibix with, or administer as an infusion with, other medicinal products. Do not add other medications to solutions containing panitumumab. <BR><BR>                                 Infuse over 60 minutes through a peripheral intravenous line or indwelling intravenous catheter. Doses higher than 1000 mg should be infused over 90 minutes. <BR>                              <BR>                           <BR>                        <BR>                        Use the diluted infusion solution of Vectibix within 6 hours of preparation if stored at room temperature, or within 24 hours of dilution if stored at 2° to 8°C (36° to 46°F). DO NOT FREEZE. <BR>                        Discard any unused portion remaining in the vial.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>